Primer on pramlintide, an amylin analog

Diabetes Educ. May-Jun 2011;37(3):426-31. doi: 10.1177/0145721711403011. Epub 2011 Apr 6.

Abstract

Purpose: Pramlintide is an injectable synthetic analog of human amylin. It is indicated for patients with type 1 or type 2 diabetes who are taking mealtime insulin but have been unable to achieve desired glucose targets. Pramlintide decreases postprandial glucose by lowering inappropriate postmeal glucagon secretion, slowing gastric emptying, and increasing satiety. As such, pramlintide targets several of the defects commonly seen in patients with diabetes. Given the unique characteristics of this agent in the treatment of diabetes, a practical guide to its use is presented.

Conclusion: Pramlintide treats diabetes with a novel mechanism of action, offering the potential for improved postprandial control and weight loss for patients with type 1 or type 2 diabetes. Providers and diabetes educators should be familiar with the utility of the medication as well as its potential limitations in order to fully educate patients and maximize treatment options for patients with diabetes.

MeSH terms

  • Diabetes Mellitus / drug therapy*
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Injections, Subcutaneous
  • Islet Amyloid Polypeptide / administration & dosage
  • Islet Amyloid Polypeptide / adverse effects
  • Islet Amyloid Polypeptide / therapeutic use*
  • Patient Education as Topic

Substances

  • Hypoglycemic Agents
  • Islet Amyloid Polypeptide
  • pramlintide